| [1] | King CH. Helminthiasis epidemiology and control[M]//Highlighting operational and implementation research for control of helminthiasis. Amsterdam: Elsevier, 2019: 11-30. | | [2] | Jensenius M, M?rch K, Yaqub S, et al. Alveolar echinococcosis[J]. Tidsskriftet, 2024: 10. | | [3] | Casulli A, Barth TFE, Tamarozzi F. Echinococcus multilocularis[J]. Trends Parasitol, 2019, 35(9): 738-739. | | [4] | 王旭, 王莹, 刘白雪, 等. 棘球绦虫和棘球蚴病的简明认知历史[J]. 中国寄生虫学与寄生虫病杂志, 2024, 42(3): 372-383. | | | Wang X, Wang Y, Liu BX, et al. A brief cognitive and historical overview of Echinococcus and echinococcosis[J]. Chin J Parasitol Parasit Dis, 2024, 42(3): 372-383. (in Chinese) | | [5] | Xu MZ, Ke F, Chai JP, et al. Progress on the HIF-1α/VEGF/VEGFR2 signal pathway in hepatic alveolar echinococcosis[J]. Front Oncol, 2025, 15: 1553125. | | [6] | Wen H, Vuitton L, Tuxun T, et al. Echinococcosis: advances in the 21st century[J]. Clin Microbiol Rev, 2019, 32(2): e00075-e00018. | | [7] | Bruschi F, Pozio E. Trichinella britovi[J]. Trends Parasitol, 2020, 36(2): 227-228. | | [8] | Taratuto AL, Venturiello SM. Trichinosis[J]. Brain Pathol, 1997, 7(1): 663-672. | | [9] | Chai JY, Jung BK, Hong SJ. Albendazole and mebendazole as anti-parasitic and anti-cancer agents: an update[J]. Korean J Parasitol, 2021, 59(3): 189-225. | | [10] | Dayan AD. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics[J]. Acta Trop, 2003, 86(2/3): 141-159. | | [11] | Lee SO, Heo SI, Nam HW, et al. Evaluation of the efficacy of anthelmintic drugs against Trichinella spiralis larvae[J]. Antibiotics (Basel), 2026, 15(2): 215. | | [12] | Gill J, Sharma A. Prospects of halofuginone as an antiprotozoal drug scaffold[J]. Drug Discov Today, 2022, 27(9): 2586-2592. | | [13] | Pines M, Spector I. Halofuginone: the multifaceted molecule[J]. Molecules, 2015, 20(1): 573-594. | | [14] | Keller TL, Zocco D, Sundrud MS, et al. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase[J]. Nat Chem Biol, 2012, 8(3): 311-317. | | [15] | Jain PP, Zhao TT, Xiong MM, et al. Halofuginone, a promising drug for treatment of pulmonary hypertension[J]. Br J Pharmacol, 2021, 178(17): 3373-3394. | | [16] | Tye MA, Payne NC, Johansson C, et al. Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance[J]. Nat Commun, 2022, 13: 4976. | | [17] | 林梦娟, 高沙沙, 赵星辰, 等. 常山酮抗原虫作用研究进展[J]. 畜牧兽医学报, 2023, 54(3): 924-933. | | | Lin MJ, Gao SS, Zhao XC, et al. Research progress on antiprotozoal activity of halofuginone[J]. Acta Vet Zootechnica Sin, 2023, 54(3): 924-933. (in Chinese) | | [18] | Granot I, Bartov I, Plavnik I, et al. Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone 1[J]. Poult Sci, 1991, 70(7): 1559-1563. | | [19] | 张秀, 魏师, 左鑫, 等. 氢溴酸常山酮对雏番鸭的毒副作用研究[J]. 广东饲料, 2023, 32(8): 28-31. | | | Zhang X, Wei S, Zuo X, et al. Toxic and side effects of halofuginone hydrobromide on Muscovy duckling[J]. Guangdong Feed, 2023, 32(8): 28-31. (in Chinese) | | [20] | Nemoto N, Udagawa T, Ohira T, et al. The roles of stress-activated Sty1 and Gcn2 kinases and of the protooncoprotein homologue Int6/eIF3e in responses to endogenous oxidative stress during histidine starvation[J]. J Mol Biol, 2010, 404(2): 183-201. | | [21] | McGaha TL, Bona C, Phelps RG, et al. Halofuginone, an inhibitor of type-Ⅰ collagen synthesis and skin sclerosis, blocks transforming-growth-factor-β-mediated Smad3 activation in fibroblasts[J]. J Investig Dermatol, 2002, 118(3): 461-470. |
|